© 2020 MJH Life Sciences and AJMC. All rights reserved.
© 2020 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
October 16th 2020, 9:00pm
Two abstracts presented at the Migraine Trust Virtual Symposium investigated lasmiditan’s safety in elderly and pediatric migraine patients.
October 5th 2020, 4:57pm
Abstracts presented at this year’s Migraine Trust International Symposium (MTIS) show how researchers analyzed the efficacy, tolerability, and safety profile of Reyvow (lasmiditan), a prescription drug used to treat migraine attacks.
October 3rd 2020, 8:00pm
Understanding and targeting all factors involved in chronic pain can improve the success of treatments.
October 3rd 2020, 5:30pm
The characteristics and degree of psychosocial morbidity in patients with orofacial pain is significantly related to the types of presenting orofacial symptoms.
September 26th 2020, 9:00pm
A study looking at older adults with chronic pain found no significant difference in cognitive performance when comparing them with matched patients who did not use medical cannabis.
September 25th 2020, 6:30pm
Patients with migraine who took lasmiditan (Reyvow) for acute pain during attacks had greater odds of reaching pain freedom, according to results of a phase 3 trial.
September 19th 2020, 7:45pm
The survey was released to mark Pain Awareness Month.
September 12th 2020, 8:45pm
Pain, fatigue, and depression are 1 cluster of symptoms afflicting 1 in 13 survivors of prostate cancer, according to a recent study.
September 10th 2020, 11:15pm
A formulation of dihydroergotamine (DHE) in a nasal powder form was no different than placebo for relief from pain and annoying symptoms at 2 hours post dose.
September 5th 2020, 4:00am
In clinical practice, lasmiditan may be given together with propranolol; investigators wanted to test the cardiovascular effects of coadministration.